{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T10:35:17Z","timestamp":1793010917874,"version":"4.5.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Aggression in pediatric populations poses significant risks to mental health and development, and drug-associated aggression may either exacerbate pre-existing behavioral problems or arise\n                      <jats:italic>de novo<\/jats:italic>\n                      following medication exposure. Existing studies, primarily based on randomized controlled trials (RCTs) and cohort designs, often underestimate real-world incidence. This study used the FDA Adverse Event Reporting System (FAERS) to systematically identify drugs associated with pediatric aggression, examining age\/sex-specific differences and time-to-onset (TTO) patterns.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective disproportionality analysis of FAERS data (2004 Q1\u20132025 Q2) for patients &amp;lt;18 years. Aggression was defined using Standardized MedDRA Queries (SMQ code: 10001488). Signals were detected using four consensus algorithms (ROR, PRR, MGPS, and BCPNN). Drugs were categorized by Anatomical Therapeutic Chemical (ATC) classification. Subgroup analyses and multivariable logistic regression were used to calculate adjusted reporting odds ratios (aRORs), and TTO was evaluated to characterize temporal patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 7,959 reports (67.75% male; median age: 9 years), 31 drugs exhibited positive signals, primarily nervous system (45.16%) and respiratory (32.26%) agents. Signals for tezacaftor, elexacaftor, macrogol, desloratadine, and ebastine were identified despite absent FDA label warnings. The strongest signals were for ebastine (ROR: 23.40) and perampanel (17.41), while montelukast had the highest case volume (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20091,392). Most drugs showed the highest aRORs in early childhood, except levetiracetam, which peaked in adolescence. Females generally showed higher risks across most agents. Median TTO ranged from rapid (anti-infectives: 2\u20133 days) to delayed (montelukast: 133 days; macrogol: 129 days).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identifies robust signals linking multiple drugs to pediatric aggression, with elevated risks observed particularly in younger children and females. These findings underscore the need for heightened clinical vigilance, consideration of demographic-specific risks, and updated regulatory labeling to improve pediatric drug safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1803086","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:37:31Z","timestamp":1780637851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of drug-related aggression in pediatric populations: a pharmacovigilance analysis using the FAERS database"],"prefix":"10.3389","volume":"14","author":[{"given":"Jing","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Fujian Children\u2019s Hospital (Fujian Branch of Shanghai Children\u2019s Medical Center)","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1097\/00004583-200012000-00007","article-title":"Oppositional defiant and conduct disorder: a review of the past 10 years, part I","volume":"39","author":"Loeber","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1469-7610.2010.02211.x","article-title":"Developmental origins of disruptive behaviour problems: the \u2018original sin\u2019 hypothesis, epigenetics and their consequences for prevention","volume":"51","author":"Tremblay","year":"2010","journal-title":"J Child Psychol Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e15337","DOI":"10.1371\/journal.pone.0015337","article-title":"Prescription drugs associated with reports of violence towards others","volume":"5","author":"Moore","year":"2010","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cppeds.2017.12.001","article-title":"Antidepressant-Induced activation in children and adolescents: risk, recognition and management","volume":"48","author":"Luft","year":"2018","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"B5","first-page":"4","article-title":"Update on the use of SSRIs and SNRIs with children and adolescents in clinical practice","volume":"25","author":"Jane Garland","year":"2016","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/jcpp.12036","article-title":"Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents","volume":"54","author":"Cortese","year":"2013","journal-title":"J Child Psychol Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1089\/cap.2015.0060","article-title":"Switch in therapy from methylphenidate to atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder: an analysis of patient records","volume":"26","author":"Warrer","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/jcpp.12381","article-title":"Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents","volume":"56","author":"Polanczyk","year":"2015","journal-title":"J Child Psychol Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"Turner","year":"2008","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jclinepi.2014.03.012","article-title":"False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies","volume":"67","author":"Glickman","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s11096-017-0570-z","article-title":"Pharmacovigilance in developing countries (part I): importance and challenges","volume":"40","author":"Elshafie","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"B18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/bcp.12222","article-title":"Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital","volume":"77","author":"Bellis","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3758\/s13415-015-0344-9","article-title":"Brain morphology of childhood aggressive behavior: a multi-informant study in school-age children","volume":"15","author":"Thijssen","year":"2015","journal-title":"Cogn Affect Behav Neurosci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41398-024-02870-7","article-title":"Genetics of child aggression, a systematic review","volume":"14","author":"Koyama","year":"2024","journal-title":"Transl Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The weber effect and the United States food and drug administration\u2019s adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/TCRM.S137144","article-title":"Relevance of the weber effect in contemporary pharmacovigilance of oncology drugs","volume":"13","author":"Arora","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jaip.2021.02.057","article-title":"A boxed warning for montelukast: the FDA perspective","volume":"9","author":"Clarridge","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","volume-title":"September 27, 2019: Meeting of the Pediatric and Drug Safety and Risk Management Committees","year":"2019"},{"key":"B25","doi-asserted-by":"publisher","first-page":"704","DOI":"10.5863\/1551-6776-28.8.704","article-title":"The impact of Montelukast\u2019s black box warning on pediatric mental health adverse event reports","volume":"28","author":"Abdelkader","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B26","author":"Jewett","year":"2024"},{"key":"B27","doi-asserted-by":"publisher","first-page":"riaf084","DOI":"10.1093\/ijpp\/riaf084","article-title":"Changes in the trend and quality of adverse drug reaction reports in the Japanese adverse drug event report database and the impact of COVID-19-related reports","author":"Tsuchiya","year":"2025","journal-title":"Int J Pharm Pract"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1001\/jama.2018.5690","article-title":"Trends in prescription medication use among children and adolescents-United States, 1999\u20132014","volume":"319","author":"Hales","year":"2018","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e00341","DOI":"10.1002\/prp2.341","article-title":"Adverse drug reactions of montelukast in children and adults","volume":"5","author":"Haarman","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100594","DOI":"10.1016\/j.waojou.2021.100594","article-title":"Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: a real-world analysis of the food and drug administration (FDA) adverse event reporting system (FAERS)","volume":"14","author":"Bian","year":"2021","journal-title":"World Allergy Organ J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/jaa.s3108","article-title":"Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines","volume":"2","author":"Rico","year":"2009","journal-title":"J Asthma Allergy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ccr3.845","article-title":"Ebastine overdose in a child","volume":"5","author":"Pecoraro","year":"2017","journal-title":"Clin Case Rep"},{"key":"B33","first-page":"25","article-title":"Desloratadine and aggressive reaction","author":"Sandberg","year":"2015","journal-title":"WHO Pharmaceut Newsl"},{"key":"B34","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/archdischild-2015-310315","article-title":"Adverse drug reactions of systemic antihistamines in children in The Netherlands","volume":"101","author":"de Vries","year":"2016","journal-title":"Arch Dis Child"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B36","volume-title":"TRIKAFTA (Elexacaftor, Tezacaftor, and Ivacaftor Tablets; Ivacaftor Tablets) Prescribing Information","year":"2025"},{"key":"B37","volume-title":"Kaftrio (Ivacaftor\/Tezacaftor\/Elexacaftor) EPAR Product Information","year":"2025"},{"key":"B38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(24)01134-6","article-title":"Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis","volume":"404","author":"Sermet-Gaudelus","year":"2024","journal-title":"Lancet"},{"key":"B39","first-page":"S234","article-title":"Classification, pharmacology, and side-effects of common laxatives","volume":"31","author":"Muller-Lissner","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/ygh2.336","article-title":"Probable neuropsychiatric toxicity of polyethylene glycol: roles of media, internet and the caregivers","volume":"1","author":"Hussain","year":"2019","journal-title":"GastroHep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e65838","DOI":"10.7759\/cureus.65838","article-title":"Polyethylene glycol misuse causing acute renal failure and metabolic acidosis requiring dialysis: a case report","volume":"16","author":"Kolosionek","year":"2024","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/MPG.0000000000003222","article-title":"Polyethylene glycol 3350 changes stool consistency and the microbiome but not behavior of CD1 mice","volume":"73","author":"Salman","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B43","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5863\/1551-6776-19.4.262","article-title":"Developmental pharmacokinetics in pediatric populations","volume":"19","author":"Lu","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1700148","DOI":"10.1183\/13993003.00148-2017","article-title":"Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice","volume":"50","author":"Benard","year":"2017","journal-title":"Eur Respir J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"107626","DOI":"10.1016\/j.eplepsyres.2025.107626","article-title":"Principal component analysis of antiseizure medication-induced hostility\/aggression and factor analysis of levetiracetam using the food and drug administration adverse event reporting system","volume":"218","author":"Hosoya","year":"2025","journal-title":"Epilepsy Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"110722","DOI":"10.1016\/j.yebeh.2025.110722","article-title":"Psychiatric disorders associated with newer antiseizure medications: a real-world disproportionality analysis of FDA adverse event reporting system","volume":"172","author":"Li","year":"2025","journal-title":"Epilepsy Behav"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2064027","DOI":"10.1155\/2018\/2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","volume":"2018","author":"Hansen","year":"2018","journal-title":"Behav Neurol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40272-024-00652-8","article-title":"The effect of levetiracetam and valproic acid treatment on anger and attention deficit hyperactivity disorder clinical features in children and adolescents with epilepsy: a prospective study","volume":"26","author":"Vatansever Pinar","year":"2024","journal-title":"Paediatr Drugs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.yebeh.2008.05.012","article-title":"Positive and negative psychotropic effects of levetiracetam","volume":"13","author":"Helmstaedter","year":"2008","journal-title":"Epilepsy Behav"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5575900","DOI":"10.1155\/2023\/5575900","article-title":"Levetiracetam-induced acute psychosis in an adolescent","volume":"2023","author":"Dhungel","year":"2023","journal-title":"Case Rep Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2165\/0002018-200831120-00006","article-title":"Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review","volume":"31","author":"Toovey","year":"2008","journal-title":"Drug Saf"},{"key":"B52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1189\/jlb.0811427","article-title":"Mechanisms of sex disparities in influenza pathogenesis","volume":"92","author":"Klein","year":"2012","journal-title":"J Leukoc Biol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40801-021-00268-1","article-title":"Delirium associations with antibiotics: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"9","author":"Teng","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"B54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12028-019-00682-y","article-title":"Clinical, electroencephalographic features and prognostic factors of cefepime-induced neurotoxicity: a retrospective study","volume":"31","author":"Li","year":"2019","journal-title":"Neurocrit Care"},{"key":"B55","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.braindev.2004.02.004","article-title":"EEG Spectral analysis in children with febrile delirium","volume":"26","author":"Onoe","year":"2004","journal-title":"Brain Dev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1097\/PEC.0000000000001175","article-title":"Delirium upon presentation to the pediatric emergency department: a case series","volume":"34","author":"Augenstein","year":"2018","journal-title":"Pediatr Emerg Care"},{"key":"B57","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/bcp.13159","article-title":"Factors affecting patient reporting of adverse drug reactions: a systematic review","volume":"83","author":"Al Dweik","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2023","journal-title":"Front Drug Saf Regul"},{"key":"B59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B60","doi-asserted-by":"publisher","first-page":"109423","DOI":"10.1016\/j.identj.2026.109423","article-title":"Real-world sodium fluoride safety signals: dual-database pharmacovigilance","volume":"76","author":"Ning","year":"2026","journal-title":"Int Dent J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40801-016-0081-6","article-title":"Seasonal and geographic variation in adverse event reporting","volume":"3","author":"Marrero","year":"2016","journal-title":"Drugs Real World Outcomes"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e732","DOI":"10.1016\/S2214-109X(24)00511-4","article-title":"Strengthening the paediatric clinical trial ecosystem to better inform policy and programmes","volume":"13","author":"Berkley","year":"2025","journal-title":"Lancet Glob Health"},{"key":"B63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13690-025-01590-8","article-title":"An overview of reviews on digital health interventions during COVID- 19 era: insights and lessons for future pandemics","volume":"83","author":"Tahmasbi","year":"2025","journal-title":"Arch Public Health"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1397566","DOI":"10.3389\/fcvm.2024.1397566","article-title":"Application of telemedicine technology for cardiovascular diseases management during the COVID-19 pandemic: a scoping review","volume":"11","author":"Asadi","year":"2024","journal-title":"Front Cardiovasc Med"}],"updated-by":[{"DOI":"10.3389\/fped.2026.2030718","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:00:00Z","timestamp":1792972800000}}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1803086\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T10:09:13Z","timestamp":1793009353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1803086\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":64,"alternative-id":["10.3389\/fped.2026.1803086"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1803086","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1803086"}}